Targeting At Risk Relatives Of Glaucoma Patients For Early Diagnosis And Treatment (TARRGET)
Funder
National Health and Medical Research Council
Funding Amount
$595,375.00
Summary
Glaucoma is the second leading cause of blindness in Australia but early detection and treatment can prevent blindness. We will recruit patients with advanced glaucoma from an Australia wide registry and refer their close relatives to have an eye exam and genetic testing to see if they are at risk of glaucoma. We will evaluate how a coordinator can improve the uptake of this screening program referring people to local eye care providers and in rural WA providing screening in 16 remote locations.
Myopia And Colour Vision: Potential Impact Of Colour Vision Gene Variation On Susceptibility To Myopia
Funder
National Health and Medical Research Council
Funding Amount
$227,947.00
Summary
The frequency of myopia has shown a rapid increase in recent years but the underlying cause remains largely unknown. Our recent work on severe myopia with dichromacy has indicated that some forms of myopia may arise through changes in cone visual pigments and the arrangement of cone photoreceptors in the retina which impact on the feedback loop between image formation and eye elongation. This study seeks to explore this link in detail in myopia patients that possess normal colour vision.
Safety And Efficacy Of A Surgically Implanted Suprachoroidal Retinal Prosthesis (Bionic Eye)
Funder
National Health and Medical Research Council
Funding Amount
$1,233,826.00
Summary
A bionic eye is a electronic device which can stimulate the remaining visual pathway in a person who is blind, to restore some basic vision. Our team have previously shown that our novel bionic eye device can be safely implanted in a patient, and can give improvements in vision when tested in a laboratory environment. The next stage of the research is to provide patients with a more advanced device, which will contain more electrodes and also be able to be taken home.
Pathogenic Role Of Changes In The Extracellular Environment Of Retinal Ganglion Cells In Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$471,979.00
Summary
There are an estimated 60 million glaucoma sufferers worldwide. Glaucoma is associated with elevated pressure within the eye but the mechanisms by which this leads to vision loss are not clear. We propose to test a new hypothesis that it is tissue stress that is responsible for the ganglion cell death in glaucoma. We propose to measure key parameters of the cellular environment in an animal model of raised intraocular pressure and determine if elevated intraocular pressure induced changes in the ....There are an estimated 60 million glaucoma sufferers worldwide. Glaucoma is associated with elevated pressure within the eye but the mechanisms by which this leads to vision loss are not clear. We propose to test a new hypothesis that it is tissue stress that is responsible for the ganglion cell death in glaucoma. We propose to measure key parameters of the cellular environment in an animal model of raised intraocular pressure and determine if elevated intraocular pressure induced changes in the cellular environment can be identified.Read moreRead less
Pathways To Treatment In Blinding Genetic Retinal Eye Diseases
Funder
National Health and Medical Research Council
Funding Amount
$556,956.00
Summary
Blinding eye diseases with genetic contributing factors affecting the retina or light-sensing part of the eye, damage the vision of millions of people worldwide. The vision impairment is irreversible, untreatable, and worsens with age. In this project, we will use technological breakthroughs in genome correction and sequencing, in combination with stem cell and mouse model applications, to develop pathways to treatment of these currently incurable diseases.
Improving Visual Outcomes In Patients With Diabetic Macular Oedema Undergoing Cataract Surgery: A Prospective Randomised Clinical Trial (the DiMECat Trial)
Funder
National Health and Medical Research Council
Funding Amount
$187,322.00
Summary
Cataract and diabetic retinopathy are the leading causes of visual loss in patients with diabetes, but unfortunately, cataract surgery in these patients often results in a loss of vision, rather than an improvement. The purpose of this study is to improve the visual outcomes in this group of patients, through the use of new, injected medicines that are given at the time of cataract surgery, thereby potentially changing current medical practice.
Saving The Optic Nerve : Manipulating The Shp2-Caveolin Axis
Funder
National Health and Medical Research Council
Funding Amount
$546,395.00
Summary
Glaucoma is a leading cause of blindness with many patients experiencing progressive vision loss despite treatment. We propose to use gene therapy techniques to manipulate the signalling pathway of Brain Derived Neurotrophic Factor and its receptor, along with biochemical and functional approaches to understand the mechanisms of glaucoma mediated eye damage and to develop new therapeutic strategies.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Neuro-feedback For Improved Efficacy Of Retinal Prostheses
Funder
National Health and Medical Research Council
Funding Amount
$653,655.00
Summary
Bionic eyes offer the possibility to return sight to the blind. Existing retinal implants are effective at delivering basic visual percepts, namely brief spots of light. Our team is now working on building the second generation of bionic eyes that include the ability to both stimulate the visual system (the retina) and record its response. By recording the evoked responses, we can adjust and optimize the stimulation to restore a persistent high spatial resolution sense of vision to the blind.